ClinicalTrials.gg
Status unknownNCT03644329Updated Aug 23, 2018

Effect of Resistance Training Variable Manipulation in Postmenopausal Breast Cancer Survivors.

An interventional study of Control group and Lower-load resistance training (LL) in Breast Cancer Survivors and Postmenopause, sponsored by Universidade Federal do Triangulo Mineiro. Status unknown at 1 site in Brazil. Open to female participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2018-08-23.

Sponsored by Universidade Federal do Triangulo Mineiro · Not applicable, Interventional, and Supportive care

How we know

The sponsor has not verified this record recently (last verified Aug 2018), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled May 2018, registered Aug 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
50 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 351 studies in Breast Neoplasms with a site in Brazil — 52 open to participants now, 111 under way, 62 of them phase 3. Breast Neoplasms · Brazil.

Planned enrollment
222nd of 309
80 · median 250
Started
2018
with 14 others
No phase
78 of 351
13 open now
Registered
184th of 351
by date

Among the 351 studies in Breast Neoplasms with a site in Brazil, this one is the 222nd largest by planned enrollment of the 309 interventional ones that give a count, is one of 15 that started in 2018, is one of 78 with no phase, and was the 184th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

52 of the 351 studies in Breast Neoplasms with a site in Brazil are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 50 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 351 studies in Breast Neoplasms with a site in Brazil, or all of them as a file.
02

Study summary

This study intends to evaluate the impact of resistance training variable manipulation (intensity and volume) on body composition, fatigability and functional capacity in postmenopausal breast cancer survivors.

Read the detailed description

The treatment for breast cancer (chemotherapy, radiotherapy and hormone therapy) provokes collateral effects,such as muscle mass and strength losses, increase of fat mass, fatigue and disability and reduced quality of life in postmenopausal breast cancer survivors. The resistance training is assumed as a non-pharmacologic interventions in postmenopausal breast cancer survivors. However, it is unclear whether the manipulation of training variables (intensity and volume) maximize the effects of resistance training on body composition, fatigability and functional capacity in postmenopausal breast cancer survivors.

03

Conditions studied

  • Breast Cancer Survivors
  • Postmenopause

Browse trials for

Keywords

  • Breast Cancer Survivors
  • resistance Training
  • fatigability
  • Body Composition
  • Functional capacity
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • breast cancer survivors;
  • No supervised or unsupervised exercise at least for six months prior to the study.

Exclusion criteria

Exclusion Criteria:

  • Alcoholics;
  • No controlled blood pressure and glucose;
  • Presence of myopathies, arthropathies, and neuropathies;
  • Presence of muscle, thromboembolic and gastrointestinal disorders, infection diseases.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Other
    Control group, CT

    In the CT, the postmenopausal breast cancer survivers does not perform exercise.

    Other: Control group

  • Experimental
    Lower-load resistance training (LL)

    In the LL, the postmenopausal breast cancer survivers will be submitted to 12 weeks of resistance training with low loads ( i.e. three sets with 30% of one-repetition maximum).

    Other: Lower-load resistance training (LL)

  • Experimental
    Higher-load resistance training (HL)

    In the HL, the postmenopausal breast cancer survivers will be submitted to 12 weeks of resistance training with high loads (i.e. three sets with 80% of one maximum repetition).

    Other: Higher-load resistance training (HL)

  • Experimental
    Higher-volume resistance training (HV)

    In the HV, the postmenopause breast cancer survivers will be submitted to 12 weeks of resistance training with high volume ( i.e. six sets with 80% one maximum repetition).

    Other: Higher-volume resistance training (HV)

Interventions

  • OtherControl group

    The volunteers will not performed the interventions.

  • OtherLower-load resistance training (LL)

    The volunteers will be perform the resistance training, three times a week for 12 weeks on non-consecutive days, three sets with 30% of 1RM and repetition until or close to failure in each set and 1.5-min of rest between sets and exercises.

  • OtherHigher-load resistance training (HL)

    The volunteers will be perform the resistance training, three times a week for 12 weeks on non-consecutive days, three sets with 80% of 1RM and repetition until or close to failure in each set and 1.5-min of rest between sets and exercises.

  • OtherHigher-volume resistance training (HV)

    The volunteers will be perform the resistance training, three times a week for 12 weeks on non-consecutive days, six sets with 80% of 1RM and repetition until or close to failure in each set and 1.5-min of rest between sets and exercises.

06

What researchers measure

Primary outcomes

  1. Evaluation the Fatigability

    The fatigability will be evaluate by 60 maximum voluntary isometric contractions (3 s contraction, 2 s rest) in knee extensors at 70 degree

    Time frame: pre and post intervention (i.e. 12 weeks)

Secondary outcomes

  1. Four- meter walk test

    The volunteers will walk 4 meter. The time will be computed to determine the gait velocity (m/s).

    Time frame: pre and post intervention (i.e. 12 weeks)

  2. Fat mass

    The fat mass (kg) will be assessed via dual-energy x-ray absorptiometry scanning (iDXA; GE Healthcare-Luna, Madison, WI; software Encore version 14.10).

    Time frame: pre intervention and post intervention (i.e. 12 weeks)

  3. Muscle strength

    Muscle strength will be evaluated by one repetition maximum (1RM) test.

    Time frame: pre and post intervention (i.e. 12 weeks)

  4. Six Minutes-walk test (6MWT)

    The volunteers will walk 6 minutes. The distance (meters) will be recorded after completes the test. The 6MWT will be performed indoor, on a flat floor in a sports court.

    Time frame: pre and post intervention (i.e. 12 weeks)

  5. Timed Up and Go test

    The volunteers will be advised to get up from a chair, walk three meters, turn around, go back to the chair, and sit down. The time (seconds) will be recorded. The test will be performed indoor, on a flat floor in a sports court.

    Time frame: pre and post intervention (i.e. 12 weeks)

  6. Five-times-sit-to-stand test

    The volunteers will rise from a chair and returned to the seated position as quickly as possible for five repetitions. The time will be recorded (seconds).

    Time frame: pre and post intervention (i.e. 12 weeks)

  7. Muscle mass

    The muscle mass (kg) will be assessed via dual-energy x-ray absorptiometry scanning (iDXA; GE Healthcare-Luna, Madison, WI; software Encore version 14.10).

    Time frame: pre and post intervention (i.e. 12 weeks)

  8. 10-meter walk test

    The volunteers will walk 10 meters. The gait speed will be evaluated (m/s). The test will be performed indoor, on a flat floor in a sports court.

    Time frame: pre and post intervention (i.e. 12 weeks)

  9. 400-meter walk test

    The volunteers will walk 400 meters. The gait speed will be evaluated (m/s). The test will be performed indoor, on a flat floor in a sports court.

    Time frame: pre and post intervention (i.e. 12 weeks)

  10. 900-meter walk test

    The volunteers will walk 900 meters. The gait speed will be evaluate (m/s). The test will be performed indoor, on a flat floor in a sports court.

    Time frame: pre and post intervention (i.e. 12 weeks)

Other outcomes

  1. Rate of force development (RFD)

    RFD will be measured by a rapid maximum isometric voluntary contraction of the one-sidedly knee extension force pulses of right leg.

    Time frame: pre and post intervention (i.e. 12 weeks)

  2. Electromyography

    Quadriceps electromyography

    Time frame: pre and post intervention (i.e. 12 weeks)

  3. Physical activity level

    The International Physical Activity Questionnaire short form (IPAQ) will be used to measure the level (time spent) of physical activities during the day. The questionnaire records the activity of four intensity levels: 1) vigorous-intensity activity such as aerobics, 2) moderate-intensity activity such as leisure cycling, 3) walking, and 4) sitting. The level of physical activity will be quantified by the sum of the four levels of intensity.

    Time frame: pre and post intervention (i.e. 12 weeks)

  4. Evaluation the quality of life

    The 36-Item Short Form Health Survey (SF-36) will be used to measure the overall quality of life aspects in the following domains: functional capacity, physical limitations, pain, overall health, vitality, social aspects, emotional limitations and mental health.

    Time frame: pre and post intervention (i.e. 12 weeks)

  5. Self-report fatigue

    The Brief Fatigue Inventory will be used for measured the self-report fatigue.

    Time frame: pre and post intervention (i.e. 12 weeks)

  6. Cytokines

    Blood samples (16 ml) will be collected between 7:30 AM and 9:00 AM after an overnight fast (10-12 hours). The blood samples (venous) will be collected by a dry tube with gel separator or EDTA (vacuum-sealed system; Vacutainer, England). The sample will be centrifuged for 10 minutes (3.000 rpm) and samples will be separated and stocked (-80 C) for futures analysis. The blood indicators will be measured (enzyme-linked immunosorbent assay method) with Touch equipment and R\&D kits (USA).

    Time frame: pre and post intervention (i.e. 12 weeks)

07

Study locations

1 of 1 sites recruiting
  • Post-degree program in physical education
    Uberaba, MG - Minas Gerais 38061-500, Brazil
    Recruiting
08

References and documents

Publications

  • Holmes J, Powell-Griner E, Lethbridge-Cejku M, Heyman K. Aging differently: Physical limitations among adults aged 50 years and over: United States, 2001-2007. NCHS Data Brief. 2009 Jul;(20):1-8. No abstract available. PubMed 19627658 ↗
  • Martin LG, Freedman VA, Schoeni RF, Andreski PM. Trends in disability and related chronic conditions among people ages fifty to sixty-four. Health Aff (Millwood). 2010 Apr;29(4):725-31. doi: 10.1377/hlthaff.2008.0746. Erratum In: Health Aff (Millwood). 2012 Mar;31(3):886. Health Aff (Millwood). 2012 Oct;31(10):2356. PubMed 20368601 ↗
  • Guralnik JM, Ferrucci L, Pieper CF, Leveille SG, Markides KS, Ostir GV, Studenski S, Berkman LF, Wallace RB. Lower extremity function and subsequent disability: consistency across studies, predictive models, and value of gait speed alone compared with the short physical performance battery. J Gerontol A Biol Sci Med Sci. 2000 Apr;55(4):M221-31. doi: 10.1093/gerona/55.4.m221. PubMed 10811152 ↗
  • Guralnik JM, Ferrucci L, Simonsick EM, Salive ME, Wallace RB. Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability. N Engl J Med. 1995 Mar 2;332(9):556-61. doi: 10.1056/NEJM199503023320902. PubMed 7838189 ↗
  • McGinn AP, Kaplan RC, Verghese J, Rosenbaum DM, Psaty BM, Baird AE, Lynch JK, Wolf PA, Kooperberg C, Larson JC, Wassertheil-Smoller S. Walking speed and risk of incident ischemic stroke among postmenopausal women. Stroke. 2008 Apr;39(4):1233-9. doi: 10.1161/STROKEAHA.107.500850. Epub 2008 Feb 21. PubMed 18292379 ↗
  • Freiberger E, de Vreede P, Schoene D, Rydwik E, Mueller V, Frandin K, Hopman-Rock M. Performance-based physical function in older community-dwelling persons: a systematic review of instruments. Age Ageing. 2012 Nov;41(6):712-21. doi: 10.1093/ageing/afs099. Epub 2012 Aug 10. PubMed 22885845 ↗
  • Steffen TM, Hacker TA, Mollinger L. Age- and gender-related test performance in community-dwelling elderly people: Six-Minute Walk Test, Berg Balance Scale, Timed Up & Go Test, and gait speeds. Phys Ther. 2002 Feb;82(2):128-37. doi: 10.1093/ptj/82.2.128. PubMed 11856064 ↗
  • Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, Scherr PA, Wallace RB. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol. 1994 Mar;49(2):M85-94. doi: 10.1093/geronj/49.2.m85. PubMed 8126356 ↗
  • Lyons RA, Perry HM, Littlepage BN. Evidence for the validity of the Short-form 36 Questionnaire (SF-36) in an elderly population. Age Ageing. 1994 May;23(3):182-4. doi: 10.1093/ageing/23.3.182. PubMed 8085500 ↗
  • Nunes PRP, Oliveira AA, Martins FM, Souza AP, Orsatti FL. Effect of resistance training volume on walking speed performance in postmenopausal women: A randomized controlled trial. Exp Gerontol. 2017 Oct 15;97:80-88. doi: 10.1016/j.exger.2017.08.011. Epub 2017 Aug 10. PubMed 28804047 ↗
  • Straight CR, Brady AO, Evans E. Sex-specific relationships of physical activity, body composition, and muscle quality with lower-extremity physical function in older men and women. Menopause. 2015 Mar;22(3):297-303. doi: 10.1097/GME.0000000000000313. PubMed 25137244 ↗
  • Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y, Schneider SM, Topinkova E, Vandewoude M, Zamboni M; European Working Group on Sarcopenia in Older People. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010 Jul;39(4):412-23. doi: 10.1093/ageing/afq034. Epub 2010 Apr 13. PubMed 20392703 ↗
  • Buchner DM, Larson EB, Wagner EH, Koepsell TD, de Lateur BJ. Evidence for a non-linear relationship between leg strength and gait speed. Age Ageing. 1996 Sep;25(5):386-91. doi: 10.1093/ageing/25.5.386. PubMed 8921145 ↗
  • Reid KF, Fielding RA. Skeletal muscle power: a critical determinant of physical functioning in older adults. Exerc Sport Sci Rev. 2012 Jan;40(1):4-12. doi: 10.1097/JES.0b013e31823b5f13. PubMed 22016147 ↗
  • Rantanen T, Guralnik JM, Ferrucci L, Penninx BW, Leveille S, Sipila S, Fried LP. Coimpairments as predictors of severe walking disability in older women. J Am Geriatr Soc. 2001 Jan;49(1):21-7. doi: 10.1046/j.1532-5415.2001.49005.x. PubMed 11207838 ↗
  • Donnelly JE, Blair SN, Jakicic JM, Manore MM, Rankin JW, Smith BK; American College of Sports Medicine. American College of Sports Medicine Position Stand. Appropriate physical activity intervention strategies for weight loss and prevention of weight regain for adults. Med Sci Sports Exerc. 2009 Feb;41(2):459-71. doi: 10.1249/MSS.0b013e3181949333. Erratum In: Med Sci Sports Exerc. 2009 Jul;41(7):1532. PubMed 19127177 ↗
  • Tseng LA, Delmonico MJ, Visser M, Boudreau RM, Goodpaster BH, Schwartz AV, Simonsick EM, Satterfield S, Harris T, Newman AB. Body composition explains sex differential in physical performance among older adults. J Gerontol A Biol Sci Med Sci. 2014 Jan;69(1):93-100. doi: 10.1093/gerona/glt027. Epub 2013 May 16. PubMed 23682159 ↗
  • Fragala MS, Clark MH, Walsh SJ, Kleppinger A, Judge JO, Kuchel GA, Kenny AM. Gender differences in anthropometric predictors of physical performance in older adults. Gend Med. 2012 Dec;9(6):445-56. doi: 10.1016/j.genm.2012.10.004. Epub 2012 Nov 2. PubMed 23123187 ↗
  • American College of Sports Medicine. American College of Sports Medicine position stand. Progression models in resistance training for healthy adults. Med Sci Sports Exerc. 2009 Mar;41(3):687-708. doi: 10.1249/MSS.0b013e3181915670. PubMed 19204579 ↗
  • Orsatti FL, Nahas EA, Maesta N, Nahas-Neto J, Burini RC. Plasma hormones, muscle mass and strength in resistance-trained postmenopausal women. Maturitas. 2008 Apr 20;59(4):394-404. doi: 10.1016/j.maturitas.2008.04.002. Epub 2008 May 21. PubMed 18499368 ↗
  • Lera Orsatti F, Nahas EA, Maesta N, Nahas Neto J, Lera Orsatti C, Vannucchi Portari G, Burini RC. Effects of resistance training frequency on body composition and metabolics and inflammatory markers in overweight postmenopausal women. J Sports Med Phys Fitness. 2014 Jun;54(3):317-25. PubMed 24739294 ↗
  • Orsatti FL, Nahas EA, Nahas-Neto J, Maesta N, Orsatti CL, Fernandes CE. Effects of resistance training and soy isoflavone on body composition in postmenopausal women. Obstet Gynecol Int. 2010;2010:156037. doi: 10.1155/2010/156037. Epub 2010 May 18. PubMed 20490353 ↗
  • Senechal M, Bouchard DR, Dionne IJ, Brochu M. The effects of lifestyle interventions in dynapenic-obese postmenopausal women. Menopause. 2012 Sep;19(9):1015-21. doi: 10.1097/gme.0b013e318248f50f. PubMed 22473250 ↗
  • Haddock BL, Wilkin LD. Resistance training volume and post exercise energy expenditure. Int J Sports Med. 2006 Feb;27(2):143-8. doi: 10.1055/s-2005-865601. PubMed 16475061 ↗
  • Thompson R. Preventing cancer: the role of food, nutrition and physical activity. J Fam Health Care. 2010;20(3):100-2. PubMed 20695357 ↗
  • Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015 Mar;65(2):87-108. doi: 10.3322/caac.21262. Epub 2015 Feb 4. PubMed 25651787 ↗
  • Krishnan K, Bassett JK, MacInnis RJ, English DR, Hopper JL, McLean C, Giles GG, Baglietto L. Associations between weight in early adulthood, change in weight, and breast cancer risk in postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2013 Aug;22(8):1409-16. doi: 10.1158/1055-9965.EPI-13-0136. Epub 2013 May 29. PubMed 23720403 ↗
  • Majed B, Moreau T, Senouci K, Salmon RJ, Fourquet A, Asselain B. Is obesity an independent prognosis factor in woman breast cancer? Breast Cancer Res Treat. 2008 Sep;111(2):329-42. doi: 10.1007/s10549-007-9785-3. Epub 2007 Oct 16. PubMed 17939036 ↗
  • Patterson RE, Cadmus LA, Emond JA, Pierce JP. Physical activity, diet, adiposity and female breast cancer prognosis: a review of the epidemiologic literature. Maturitas. 2010 May;66(1):5-15. doi: 10.1016/j.maturitas.2010.01.004. Epub 2010 Jan 25. PubMed 20097494 ↗
  • Stone P, Hardy J, Broadley K, Tookman AJ, Kurowska A, A'Hern R. Fatigue in advanced cancer: a prospective controlled cross-sectional study. Br J Cancer. 1999 Mar;79(9-10):1479-86. doi: 10.1038/sj.bjc.6690236. PubMed 10188894 ↗
  • Courneya KS. Exercise in cancer survivors: an overview of research. Med Sci Sports Exerc. 2003 Nov;35(11):1846-52. doi: 10.1249/01.MSS.0000093622.41587.B6. PubMed 14600549 ↗
  • Schmitz KH, Courneya KS, Matthews C, Demark-Wahnefried W, Galvao DA, Pinto BM, Irwin ML, Wolin KY, Segal RJ, Lucia A, Schneider CM, von Gruenigen VE, Schwartz AL; American College of Sports Medicine. American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc. 2010 Jul;42(7):1409-26. doi: 10.1249/MSS.0b013e3181e0c112. Erratum In: Med Sci Sports Exerc. 2011 Jan;43(1):195. PubMed 20559064 ↗
  • Martins da Silva RC, Rezende LF. Assessment of impact of late postoperative physical functional disabilities on quality of life in breast cancer survivors. Tumori. 2014 Jan-Feb;100(1):87-90. doi: 10.1700/1430.15821. PubMed 24675497 ↗
  • Rietman JS, Geertzen JH, Hoekstra HJ, Baas P, Dolsma WV, de Vries J, Groothoff JW, Eisma WH, Dijkstra PU. Long term treatment related upper limb morbidity and quality of life after sentinel lymph node biopsy for stage I or II breast cancer. Eur J Surg Oncol. 2006 Mar;32(2):148-52. doi: 10.1016/j.ejso.2005.11.008. Epub 2006 Jan 4. PubMed 16387467 ↗
  • Goedendorp MM, Gielissen MF, Verhagen CA, Bleijenberg G. Development of fatigue in cancer survivors: a prospective follow-up study from diagnosis into the year after treatment. J Pain Symptom Manage. 2013 Feb;45(2):213-22. doi: 10.1016/j.jpainsymman.2012.02.009. Epub 2012 Aug 25. PubMed 22926087 ↗
  • Berger AM, Mooney K, Alvarez-Perez A, Breitbart WS, Carpenter KM, Cella D, Cleeland C, Dotan E, Eisenberger MA, Escalante CP, Jacobsen PB, Jankowski C, LeBlanc T, Ligibel JA, Loggers ET, Mandrell B, Murphy BA, Palesh O, Pirl WF, Plaxe SC, Riba MB, Rugo HS, Salvador C, Wagner LI, Wagner-Johnston ND, Zachariah FJ, Bergman MA, Smith C; National comprehensive cancer network. Cancer-Related Fatigue, Version 2.2015. J Natl Compr Canc Netw. 2015 Aug;13(8):1012-39. doi: 10.6004/jnccn.2015.0122. PubMed 26285247 ↗
  • Barsevick AM, Irwin MR, Hinds P, Miller A, Berger A, Jacobsen P, Ancoli-Israel S, Reeve BB, Mustian K, O'Mara A, Lai JS, Fisch M, Cella D; National Cancer Institute Clinical Trials Planning Meeting. Recommendations for high-priority research on cancer-related fatigue in children and adults. J Natl Cancer Inst. 2013 Oct 2;105(19):1432-40. doi: 10.1093/jnci/djt242. Epub 2013 Sep 18. PubMed 24047960 ↗
  • Steindorf K, Schmidt ME, Klassen O, Ulrich CM, Oelmann J, Habermann N, Beckhove P, Owen R, Debus J, Wiskemann J, Potthoff K. Randomized, controlled trial of resistance training in breast cancer patients receiving adjuvant radiotherapy: results on cancer-related fatigue and quality of life. Ann Oncol. 2014 Nov;25(11):2237-2243. doi: 10.1093/annonc/mdu374. Epub 2014 Aug 5. PubMed 25096607 ↗
  • Hagstrom AD, Marshall PW, Lonsdale C, Cheema BS, Fiatarone Singh MA, Green S. Resistance training improves fatigue and quality of life in previously sedentary breast cancer survivors: a randomised controlled trial. Eur J Cancer Care (Engl). 2016 Sep;25(5):784-94. doi: 10.1111/ecc.12422. Epub 2015 Nov 23. PubMed 26593858 ↗
  • Serra MC, Ryan AS, Ortmeyer HK, Addison O, Goldberg AP. Resistance training reduces inflammation and fatigue and improves physical function in older breast cancer survivors. Menopause. 2018 Feb;25(2):211-216. doi: 10.1097/GME.0000000000000969. PubMed 28832427 ↗
  • Buffart LM, Ros WJ, Chinapaw MJ, Brug J, Knol DL, Korstjens I, van Weert E, Mesters I, van den Borne B, Hoekstra-Weebers JE, May AM. Mediators of physical exercise for improvement in cancer survivors' quality of life. Psychooncology. 2014 Mar;23(3):330-8. doi: 10.1002/pon.3428. Epub 2013 Oct 14. PubMed 24123482 ↗
  • Kalter J, Kampshoff CS, Chinapaw MJ, VAN Mechelen W, Galindo-Garre F, Schep G, Verdonck-DE Leeuw IM, Brug J, Buffart LM. Mediators of Exercise Effects on HRQoL in Cancer Survivors after Chemotherapy. Med Sci Sports Exerc. 2016 Oct;48(10):1859-65. doi: 10.1249/MSS.0000000000000976. PubMed 27128668 ↗
  • Hunter SK. Performance Fatigability: Mechanisms and Task Specificity. Cold Spring Harb Perspect Med. 2018 Jul 2;8(7):a029728. doi: 10.1101/cshperspect.a029728. PubMed 28507192 ↗
  • Enoka RM, Duchateau J. Translating Fatigue to Human Performance. Med Sci Sports Exerc. 2016 Nov;48(11):2228-2238. doi: 10.1249/MSS.0000000000000929. PubMed 27015386 ↗
  • Enoka RM, Baudry S, Rudroff T, Farina D, Klass M, Duchateau J. Unraveling the neurophysiology of muscle fatigue. J Electromyogr Kinesiol. 2011 Apr;21(2):208-19. doi: 10.1016/j.jelekin.2010.10.006. Epub 2010 Nov 10. PubMed 21071242 ↗
  • Enoka RM, Duchateau J. Muscle fatigue: what, why and how it influences muscle function. J Physiol. 2008 Jan 1;586(1):11-23. doi: 10.1113/jphysiol.2007.139477. Epub 2007 Aug 16. PubMed 17702815 ↗
  • Hunter SK, Pereira HM, Keenan KG. The aging neuromuscular system and motor performance. J Appl Physiol (1985). 2016 Oct 1;121(4):982-995. doi: 10.1152/japplphysiol.00475.2016. Epub 2016 Aug 11. PubMed 27516536 ↗
  • Poole DC, Burnley M, Vanhatalo A, Rossiter HB, Jones AM. Critical Power: An Important Fatigue Threshold in Exercise Physiology. Med Sci Sports Exerc. 2016 Nov;48(11):2320-2334. doi: 10.1249/MSS.0000000000000939. PubMed 27031742 ↗
  • Burnley M, Jones AM. Power-duration relationship: Physiology, fatigue, and the limits of human performance. Eur J Sport Sci. 2018 Feb;18(1):1-12. doi: 10.1080/17461391.2016.1249524. Epub 2016 Nov 3. PubMed 27806677 ↗
  • Muscaritoli M, Anker SD, Argiles J, Aversa Z, Bauer JM, Biolo G, Boirie Y, Bosaeus I, Cederholm T, Costelli P, Fearon KC, Laviano A, Maggio M, Rossi Fanelli F, Schneider SM, Schols A, Sieber CC. Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) "cachexia-anorexia in chronic wasting diseases" and "nutrition in geriatrics". Clin Nutr. 2010 Apr;29(2):154-9. doi: 10.1016/j.clnu.2009.12.004. Epub 2010 Jan 8. PubMed 20060626 ↗
  • Marsh AP, Miller ME, Saikin AM, Rejeski WJ, Hu N, Lauretani F, Bandinelli S, Guralnik JM, Ferrucci L. Lower extremity strength and power are associated with 400-meter walk time in older adults: The InCHIANTI study. J Gerontol A Biol Sci Med Sci. 2006 Nov;61(11):1186-93. doi: 10.1093/gerona/61.11.1186. PubMed 17167161 ↗
  • Maffiuletti NA, Aagaard P, Blazevich AJ, Folland J, Tillin N, Duchateau J. Rate of force development: physiological and methodological considerations. Eur J Appl Physiol. 2016 Jun;116(6):1091-116. doi: 10.1007/s00421-016-3346-6. Epub 2016 Mar 3. PubMed 26941023 ↗
  • Fink J, Kikuchi N, Yoshida S, Terada K, Nakazato K. Impact of high versus low fixed loads and non-linear training loads on muscle hypertrophy, strength and force development. Springerplus. 2016 May 20;5(1):698. doi: 10.1186/s40064-016-2333-z. eCollection 2016. PubMed 27350928 ↗
  • Gurjao AL, Gobbi LT, Carneiro NH, Goncalves R, Ferreira de Moura R, Cyrino ES, Altimari LR, Gobbi S. Effect of strength training on rate of force development in older women. Res Q Exerc Sport. 2012 Jun;83(2):268-75. doi: 10.1080/02701367.2012.10599857. PubMed 22808712 ↗
  • Aagaard P, Simonsen EB, Andersen JL, Magnusson P, Dyhre-Poulsen P. Increased rate of force development and neural drive of human skeletal muscle following resistance training. J Appl Physiol (1985). 2002 Oct;93(4):1318-26. doi: 10.1152/japplphysiol.00283.2002. PubMed 12235031 ↗
  • Burnley M. Estimation of critical torque using intermittent isometric maximal voluntary contractions of the quadriceps in humans. J Appl Physiol (1985). 2009 Mar;106(3):975-83. doi: 10.1152/japplphysiol.91474.2008. Epub 2009 Jan 15. PubMed 19150854 ↗
  • Klass M, Baudry S, Duchateau J. Voluntary activation during maximal contraction with advancing age: a brief review. Eur J Appl Physiol. 2007 Jul;100(5):543-51. doi: 10.1007/s00421-006-0205-x. Epub 2006 Jun 9. PubMed 16763836 ↗
  • Strasser B, Steindorf K, Wiskemann J, Ulrich CM. Impact of resistance training in cancer survivors: a meta-analysis. Med Sci Sports Exerc. 2013 Nov;45(11):2080-90. doi: 10.1249/MSS.0b013e31829a3b63. PubMed 23669878 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2018 (actual). Primary completion is estimated for Nov 2018, 5 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 5 months is below that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2018
First posted
Aug 23, 2018
StartActual
May 13, 2018
Primary completionEst.
Nov 10, 2018
CompletionEst.
Dec 20, 2019
Last update
Aug 23, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 23, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03644329
Lead sponsor
Universidade Federal do Triangulo Mineiro
Responsible party
Fábio Lera Orsatti (Principal Investigator, Universidade Federal do Triangulo Mineiro) — Principal investigator
First posted
Aug 23, 2018
Start date
May 13, 2018
Primary completion
Nov 10, 2018 (estimated)
Completion
Dec 20, 2019 (estimated)
Last update
Aug 23, 2018

Study contacts

Fábio L Orsatti, PhD
Contact
fabiorsatti@gmail.com
+55343700-6634
Fábio L Orsatti, PhD
principal investigator · Federal University of Triângulo Mineiro

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion